ClinCalc Pro
Menu
Antimuscarinic (anticholinergic) bladder relaxant Pregnancy: Use with caution; limited data. Only if essential.

Oxybutynin

Brand names: Ditropan, Kentera (patch), Lyrinel XL

Adult dose

Dose: Immediate-release: 5 mg 2–3 times daily; Modified-release: 5–10 mg once daily
Route: Oral or transdermal patch
Frequency: 2–3 times daily (IR); once daily (MR); twice weekly (patch)
Max: 15–20 mg/day oral; 36 mg/2 days (patch)
OAB/detrusor overactivity: 5 mg BD-TDS (IR) or 5–10 mg OD (MR). Kentera patch (3.9 mg/24h): apply to abdomen/buttock twice weekly. MR formulation preferred (fewer CNS side effects). Elderly: start 2.5 mg BD.

Paediatric dose

Dose: 0.2 mg/kg
Route: Oral
Frequency: Two to three times daily
Max: 5 mg/dose (≥5 years)
Concentration: 2.5 mg/ml
≥5 years (neurogenic bladder/OAB): 2.5–5 mg two to three times daily. Do not use in children <5 years. Neurogenic bladder in children: paediatric urology/neurology specialist.

Dose adjustments

Renal

Use with caution in severe renal impairment.

Hepatic

Use with caution in severe hepatic impairment.

Paediatric weight-based calculator

≥5 years (neurogenic bladder/OAB): 2.5–5 mg two to three times daily. Do not use in children <5 years. Neurogenic bladder in children: paediatric urology/neurology specialist.

Clinical pearls

  • Anticholinergic burden in elderly is cumulative — consider switching to beta-3 agonist (mirabegron) with lower cognitive risk
  • MR formulation has fewer CNS and GI side effects than IR
  • Transdermal patch has even fewer systemic side effects (bypasses first-pass metabolism and reduces active metabolite levels)
  • Cognitive impairment: avoid in elderly with dementia or MCI (STOPP/START criteria)
  • Sugarless gum/sweets for dry mouth

Contraindications

  • Urinary retention
  • Narrow-angle glaucoma
  • Myasthenia gravis
  • Severe GI motility disorders
  • Toxic megacolon

Side effects

  • Dry mouth (very common — anticholinergic)
  • Constipation
  • Blurred vision
  • Urinary retention (paradoxical)
  • Cognitive impairment (elderly — anticholinergic burden)
  • Tachycardia
  • Dry skin and flushing
  • Drowsiness

Interactions

  • Other antimuscarinics — additive effects (avoid combinations)
  • Cholinesterase inhibitors (donepezil) — antagonistic (reduce dementia drug efficacy)
  • Amantadine, antipsychotics — additive anticholinergic burden

Monitoring

  • Urinary symptoms and residual volume
  • Cognitive function (elderly)
  • IOP (glaucoma risk)
  • GI function

Reference: BNFc; BNF; NICE NG123 Urinary Incontinence; BNFc; STOPP/START criteria. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.